Journal of Biological Chemistry 'Under Review': What Each Status Means

JBC operates the Associate Editor + Editorial Board Member (EBM) model. JBC's editorial model uses associate editors who are active researchers in the field, and the ASBMB's streamlined process means reviews come back quickly. The associate editor reads the paper and evaluates biological-chemistry field fit, scientific rigor, and reproducibility. An associate editor at JBC typically handles 30 to 50 manuscripts per quarter and spends 30 to 60 minutes on the initial read; JBC associate editors are working academics fitting JBC editorial work around their own research.

JBC editorial culture is decisive: only a small fraction of submitted papers are rejected right away, in most cases because the Associate Editor views the manuscript to be outside the biological chemistry field and/or better suited to a more specialized audience. The low ~20 percent desk rejection rate distinguishes JBC from the 80+ percent desk-rejection rate of broader-significance flagships.

Before the paper reaches Editorial Board Member review, a JBC associate editor evaluates whether the work fits the biological-chemistry field and warrants JBC's editorial slots. Only a small fraction of submitted papers are rejected right away, in most cases because the Associate Editor views the manuscript to be outside the biological chemistry field and/or better suited to a more specialized audience. JBC's 20 percent desk rejection rate is unusually low for a field-leading journal because JBC's mission is to publish biological-chemistry research broadly.

The JBC editorial office confirms files are complete: manuscript with figures embedded, supplementary information separate, reporting checklists where applicable (ARRIVE for animal work, MIQE for quantitative PCR), cover letter directed to the associate editor, conflict-of-interest declarations, ethics-statement documentation, IRB approvals, and data-availability statement.

The associate editor reads the paper and evaluates biological-chemistry field fit, scientific rigor, and JBC family routing.

In parallel with the primary associate editor's read, ambiguous-fit papers are discussed across the JBC associate editor team where peer associate editors weigh in on whether the paper would fit better at JBC or at sister ASBMB journals (Molecular and Cellular Proteomics, Journal of Lipid Research). This editorial-team discussion runs alongside the desk-screen and adds 2 to 5 days to the timeline that is invisible to the author in the portal.

JBC associate editors typically invite 2 to 3 Editorial Board Members (with 2 EBMs being the most common configuration), and the reviewer recruitment window typically takes 5 to 10 days. In plain reviewer-count terms, that usually means two reviewers, with recruitment often taking 5 to 10 days before both reports are in motion. JBC's EBMs are experts in the field that receive training in peer review to uphold JBC's high standards of rigor and reproducibility and have made a commitment to review papers over a 5-year term. This EBM commitment model means recruitment is faster than at journals that recruit ad-hoc external reviewers.

Once EBMs agree to review, the typical JBC peer-review cycle lasts 2 to 3 weeks per reviewer. Referees are asked to return their assessment in 14 days for a regular publication and 5 days for an Accelerated Communication. Reviewers are asked to evaluate biological-chemistry rigor, reproducibility, and methodological clarity. Reviewer reports for JBC tend to be focused; 1500 to 3000 word reports are typical given the 14-day reviewer target.

After reports return, the associate editor synthesizes them. The 3 to 6 week first-decision time applies to papers that reach external peer review.

• Rejection within 1 to 5 days: Administrative issue or immediate scope mismatch.
• Rejection within 5 to 10 days: Associate editor desk rejection per the ~20 percent figure.
• Still Under Review after 2 weeks: Strong signal. Paper passed the Associate Editor filter and is in active EBM review.
• Still Under Review after 8 weeks: Reviewer-recruitment or reviewer-report delay. A polite inquiry via the Editorial Manager portal is appropriate.
• Status changes to "Decision Pending": Reports are in; expect a decision within 1 week.

This is the most common anxiety we hear from JBC authors during the active editorial window. The honest answer: no, 4 weeks at Under Review puts you in the normal middle of JBC's 3 to 6 week first-decision distribution. Reports may already be in editorial synthesis with the associate editor preparing the recommendation. Most reviewer-driven delays come from EBM scheduling (EBMs are working academics with 5-year peer-review commitments who fit JBC review around their own research) rather than slow reviews because the 14-day reviewer target keeps active review fast. If the portal still says Under Review at the 6-week mark, the most likely explanation is that one of the assigned EBMs asked for an extension and the associate editor granted it. This is normal practice at JBC.

What you should NOT do during the 4-to-6-week window is email the editorial office. JBC associate editors are managing 30+ active papers; an inquiry at 4 weeks adds friction without accelerating the timeline.

If your JBC paper is rejected after review, the natural cascade depends on what the EBMs and associate editor cited:

Molecular and Cellular Proteomics (MCP) is the natural ASBMB cascade for proteomics-focused biological-chemistry papers. ASBMB supports manuscript-transfer with reviewer reports preserved.

Journal of Lipid Research (JLR) is the ASBMB cascade for lipid-biochemistry papers.

Biochemistry (ACS) is the external ACS cascade for biological-chemistry papers. ACS uses ACS Paragon Plus at acsparagonplus.acs.org; editorial contact via acs.bichaw@acs.org.

Biochemical Journal (Portland Press) is the external Biochemical Society cascade for biological-chemistry papers.

PLOS ONE is the broader PLOS open-access cascade for technically-sound biological-chemistry papers. PLOS uses Editorial Manager at editorialmanager.com/pone; editorial contact plosone@plos.org.

Scientific Reports is the Nature Portfolio open-access cascade for technically-sound biological-chemistry papers.

ASBMB asks EBMs at JBC to evaluate four things specifically. The table below maps each to actionable preparation.

This guide tells you what Journal of Biological Chemistry editors look for during the status window. Manusights has reviewed 50+ manuscripts targeting Journal of Biological Chemistry or adjacent ASBMB and biochemical journals; full Manusights reviews include a 60-day money-back guarantee, and we do not train AI on customer manuscripts. Three patterns explain most of the JBC reviewer-risk feedback we see before submission.

Journal of Biological Chemistry manuscripts framed for a specialized audience instead of biological chemistry. A common JBC failure pattern is a strong experiment packaged as a narrow organism, disease, enzyme, or pathway story. The abstract may be accurate, but the introduction does not make the biological-chemistry principle legible to a broader JBC reader. Associate Editors and EBMs then treat the manuscript as better suited to a specialist journal. The fix usually sits in the title, abstract, final introduction paragraph, and first discussion section: state the mechanism, biochemical constraint, structure-function relationship, or method capability that travels beyond the immediate model system.

Check whether your JBC biological-chemistry framing is broad enough ->

Journal of Biological Chemistry manuscripts with methods and raw-data gaps that slow EBM review. JBC's EBM model rewards manuscripts whose methods section, figure legends, and Supporting Information can be checked quickly. We often see promising papers lose reviewer confidence because protein purification conditions, enzyme-kinetics fitting, structural-validation settings, antibody identifiers, plasmid details, original blot or gel files, or statistical-analysis choices are scattered or missing. The issue is not just formatting. It changes how the reviewer reads every result figure. A reviewer who cannot audit the methods will usually ask for expanded methods, raw data, and sometimes repeated controls.

Check whether your JBC methods and raw-data package is EBM-ready ->

Journal of Biological Chemistry manuscripts that need ASBMB routing before the first upload. Some papers are rigorous but are centered on proteomics, lipid biology, disease biology, or a technology resource rather than broad biological chemistry. In those cases, the cover letter and abstract can make JBC look like a prestige default instead of a deliberate match. The stronger move is to decide whether the manuscript should be sharpened for JBC, routed to Molecular and Cellular Proteomics or Journal of Lipid Research, or sent to a broader technical-soundness journal. That routing decision is easier before the status turns Under Review than after an EBM report has already framed the issue.

Check whether your JBC ASBMB routing is stronger than the fallback route ->

This page was created from ASBMB's public peer review documentation at jbcresources.asbmb.org/peer-review-at-jbc, JBC Elsevier author guide (3 to 6 week first decision, ~20 percent desk rejection, 14-day reviewer target for regular publications, 5-day target for Accelerated Communications, EBM training and 5-year commitment model, typically 2 EBMs per paper), and Manusights pre-submission review experience with JBC-targeted manuscripts. Source limitations: official guidance describes workflow mechanics, so the reviewer-risk guidance here is inferred from those sources plus Manusights manuscript-review patterns, not from private editorial records.

For the biological-chemistry landscape beyond JBC, see Molecular and Cellular Proteomics (ASBMB proteomics specialty), Journal of Lipid Research (ASBMB lipid specialty), Biochemistry (ACS biochemistry), Biochemical Journal (Biochemical Society), and broader open-access alternatives (PLOS ONE, Scientific Reports). The choice across these titles depends on whether the central contribution is broad biological-chemistry (JBC), proteomics (MCP), lipid biochemistry (JLR), ACS biochemistry (Biochemistry), Biochemical Society biochemistry (Biochemical Journal), or open-access (PLOS ONE, Scientific Reports).

Reviewers at JBC typically draw from 2 trained Editorial Board Members with 5-year peer-review commitments. The EBM model means reviewer expertise is consistent across submissions, and preparing a response template that addresses both rigor and methodological-clarity perspectives accelerates revision rounds substantially.

For a pre-upload check of your manuscript against the JBC biological-chemistry-rigor bar before submission, our JBC pre-submission diagnostic flags the framing and methods-documentation weaknesses most likely to surface in EBM reports.